Molecular Partners Showcases Bispecific Radio-DARPins at Gordon Research Conference
Molecular Partners presented data on its bispecific Radio-DARPins at the Gordon Research Conference, focusing on multispecific approaches to improve precision in heterogeneous cancers. The company provided pipeline updates, noting that lead candidate MP0712 is in a multicenter US Phase 1/2a trial and MP0726 is expected to achieve first human imaging this year.
Key figures
- Mp0712 status
- multicenter US Phase 1/2a trial
- Mp0726 status
- first human imaging expected this year
- Third program announcement
- 2026
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.